Retatrutide Genopharm 20 mg

Retatrutide is an investigational triple-agonist peptide that activates the GLP-1, GIP and glucagon receptors simultaneously, placing it in the same metabolic peptide category as GLP-1 and GIP-based compounds but with a broader mechanism. This Genopharm pack contains one vial holding 20 mg of Retatrutide as a dry powder, together with a 2 ml ampoule of Sodium Chloride injection U.S.P. (0.9 % w/v) for reconstitution.

By acting on all three receptors at once, Retatrutide reduces appetite, increases satiety, promotes fat breakdown and supports blood sugar control more comprehensively than single- or dual-receptor peptides. Clinical research has shown dose-dependent weight reduction, with higher doses associated with greater results. The 20 mg vial is a multi-dose container: it holds several weekly doses rather than a single administration.

Najważniejsze korzyści

• Triple mechanism (GLP-1, GIP and glucagon receptors) for a broader metabolic effect than single-target peptides
• Reduces appetite and increases feelings of fullness
• Promotes breakdown of fat reserves
• Supports improved metabolic rate and blood sugar control
• Dose-dependent results demonstrated in clinical research
• Solvent ampoule included in the pack; produced under GMP (Good Manufacturing Practice)